MetaCap

Palisade Bio (PALI) vs Sutro Biopharma (STRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sutro Biopharma (STRO) has outperformed Palisade Bio (PALI) over the past year, gaining 2.4% versus a loss of 60.6%. Over five years, STRO leads with a -94.7% price change compared with -100.0% for PALI. Palisade Bio is the larger company by market cap ($150.7 million vs $142.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PALI-60.57%STRO+2.38%
+409%+163%-83%
Nov 21, 20251 yearNov 20, 2026
PALI-99.95%STRO-95.10%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PALI versus STRO key metrics
MetricPALISTRO
Share price$0.8399$8.60
Market cap$150.74M$142.77M
1-day change-9.24%-1.38%
YTD return-64.26%-25.67%
1-year return-60.57%+2.38%
5-year return-99.95%-94.68%
P/E ratio (TTM)0.91—
EPS (TTM)$0.92$-12.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$102.48M
Revenue growth (YoY)—+65.18%
Net income (latest FY)$-16.78M$-191.09M
Operating margin—-154.53%
Net margin—-186.45%
52-week high$2.86$43.85
52-week low$0.8381$7.15
Distance from 52-week high-70.63%-80.39%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+935.84%+419.65%
Average volume3.19M304.90K
Shares outstanding179.28M16.60M
Employees14129
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STRO has outperformed PALI by 62.9 percentage points over the past year.

About Palisade Bio

PALI stock →

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees

About Sutro Biopharma

STRO stock →

Sutro Biopharma, Inc. operates as an oncology company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 129 employees

PALI vs STRO FAQ

Which is bigger, Palisade Bio or Sutro Biopharma?

Palisade Bio (PALI) is larger, with a market capitalization of $150.74M compared with $142.77M for Sutro Biopharma (STRO).

Which stock has performed better over the past year, PALI or STRO?

STRO returned +2.38% over the past 12 months, compared with -60.57% for PALI (price return, excluding dividends). Past performance does not predict future results.

Are Palisade Bio and Sutro Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons